Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015



 Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The
                   Acute Leukemia Markets Beginning In 2015

Interviewed Experts Cite High Unmet Need for Better-Tolerated Treatments
Directed Toward Elderly Patients with Acute Leukemia, According to Findings
from Decision Resources

PR Newswire

BURLINGTON, Mass., Jan. 30, 2013

BURLINGTON, Mass., Jan. 30, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, forecasts the launch of new agents positioned for the
treatment of both acute lymphoblastic leukemia (ALL) and acute myeloid
leukemia (AML) through 2018. According to two Niche Markets and Rare Diseases
reports, Acute Lymphoblastic Leukemia and  Acute Myeloid Leukemia, novel
targeted therapies hold the most promise for improving outcomes for patients
with acute leukemia. Interviewed experts are enthusiastic about the potential
of Amgen/MicroMet's blinatumomab–a first-in-class bispecific T-cell
engager–for the treatment of ALL. Experts also highlight the potential of
Ambit Biosciences/Astellas Pharma's quizartinib in AML: quizartinib will be
the first agent that will be targeted to a specific AML sub-population, those
patients with mutations in FLT3. However, clinical benefit in
relapsed/refractory patients that do not harbor mutations in FLT3 suggests
that uptake of the drug in a wider population is anticipated.

"The late-stage acute leukemia pipeline has shown a lot of promise lately, and
experts are excited at the prospect of having more targeted therapies
available to add to traditional chemotherapy options," said Decision Resources
Therapy Leader Joanne Graham, Ph.D. "New formulations of existing
chemotherapies will also play a role in the late-stage pipeline. Despite the
promise of novel targeted drugs, there is no doubt that the future treatment
of acute leukemia will continue to rely heavily on chemotherapies."  

These reports also find that, despite the launch of several new agents
throughout the forecast period, there are still high levels of unmet need in
the acute leukemia space, especially for treatments that provide improved
efficacy outcomes for, and are less toxic to older patients, as well as
treatments tailored towards currently underserved populations, such as T-cell
leukemia.

"Acute lymphoblastic leukemia is the most commonly diagnosed cancer in
children but only accounts for a minority of adult leukemias," said Dr.
Graham. "The prognosis for adult patients is discouraging, with an overall
adult survival rate of approximately 40 percent, compared with 80 percent in
children. As this demographic grows, so does the need for treatments directed
at older and adult patients whose disease is often more aggressive."

About Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia are  offered as part
of Decision Resources' Niche Markets and Rare Diseases service. Each report
assesses opportunity in a select drug market across the United States, France,
Germany, Italy, Spain and the United Kingdom. The reports provides detailed
coverage of patient populations, current therapies, unmet needs and emerging
therapies, and includes primary research with country-specific thought
leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:
Decision Resources             Decision Resources Group
Allison Thrower                Liz Marshall
781-993-2604                   781-993-2563
athrower@dresourcesgroup.com   emarshall@dresourcesgroup.com

SOURCE Decision Resources

Website: http://www.decisionresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement